Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
PMD's Cash to Debt is ranked higher than
82% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. PMD: No Debt )
PMD' s 10-Year Cash to Debt Range
Min: 2.5   Max: No Debt
Current: No Debt

Equity to Asset 0.74
PMD's Equity to Asset is ranked higher than
74% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. PMD: 0.74 )
PMD' s 10-Year Equity to Asset Range
Min: 0.7   Max: 0.93
Current: 0.74

0.7
0.93
Interest Coverage No Debt
PMD's Interest Coverage is ranked higher than
80% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. PMD: No Debt )
PMD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 6
Z-Score: 15.31
M-Score: -3.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 21.24
PMD's Operating margin (%) is ranked higher than
95% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. PMD: 21.24 )
PMD' s 10-Year Operating margin (%) Range
Min: 2.05   Max: 32.29
Current: 21.24

2.05
32.29
Net-margin (%) 14.16
PMD's Net-margin (%) is ranked higher than
91% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. PMD: 14.16 )
PMD' s 10-Year Net-margin (%) Range
Min: 1.48   Max: 20.93
Current: 14.16

1.48
20.93
ROE (%) 30.99
PMD's ROE (%) is ranked higher than
98% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. PMD: 30.99 )
PMD' s 10-Year ROE (%) Range
Min: 3.44   Max: 45.52
Current: 30.99

3.44
45.52
ROA (%) 22.99
PMD's ROA (%) is ranked higher than
98% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. PMD: 22.99 )
PMD' s 10-Year ROA (%) Range
Min: 2.56   Max: 36.97
Current: 22.99

2.56
36.97
ROC (Joel Greenblatt) (%) 62.86
PMD's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. PMD: 62.86 )
PMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.71   Max: 233.78
Current: 62.86

9.71
233.78
Revenue Growth (%) 9.50
PMD's Revenue Growth (%) is ranked higher than
79% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.40 vs. PMD: 9.50 )
PMD' s 10-Year Revenue Growth (%) Range
Min: -10   Max: 21.9
Current: 9.5

-10
21.9
EBITDA Growth (%) 11.30
PMD's EBITDA Growth (%) is ranked higher than
81% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. PMD: 11.30 )
PMD' s 10-Year EBITDA Growth (%) Range
Min: -28   Max: 46.8
Current: 11.3

-28
46.8
EPS Growth (%) 12.90
PMD's EPS Growth (%) is ranked higher than
82% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. PMD: 12.90 )
PMD' s 10-Year EPS Growth (%) Range
Min: -54.7   Max: 138.1
Current: 12.9

-54.7
138.1
» PMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

PMD Guru Trades in Q1 2013

Jim Simons 330,800 sh (+3.6%)
Chuck Royce 137,500 sh (unchged)
» More
Q2 2013

PMD Guru Trades in Q2 2013

Jim Simons 343,500 sh (+3.84%)
Chuck Royce 137,500 sh (unchged)
» More
Q3 2013

PMD Guru Trades in Q3 2013

Jim Simons 374,000 sh (+8.88%)
Chuck Royce 137,500 sh (unchged)
» More
Q4 2013

PMD Guru Trades in Q4 2013

Jim Simons 403,200 sh (+7.81%)
Chuck Royce 137,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PMD



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.30
PMD's P/E(ttm) is ranked higher than
71% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.90 vs. PMD: 23.30 )
PMD' s 10-Year P/E(ttm) Range
Min: 9.01   Max: 53.94
Current: 23.3

9.01
53.94
P/B 7.29
PMD's P/B is ranked lower than
57% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. PMD: 7.29 )
PMD' s 10-Year P/B Range
Min: 1.98   Max: 13.13
Current: 7.29

1.98
13.13
P/S 3.33
PMD's P/S is ranked higher than
64% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. PMD: 3.33 )
PMD' s 10-Year P/S Range
Min: 0.92   Max: 4.52
Current: 3.33

0.92
4.52
PFCF 21.60
PMD's PFCF is ranked higher than
65% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.94 vs. PMD: 21.60 )
PMD' s 10-Year PFCF Range
Min: 6.64   Max: 88.21
Current: 21.6

6.64
88.21
EV-to-EBIT 15.02
PMD's EV-to-EBIT is ranked higher than
75% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.60 vs. PMD: 15.02 )
PMD' s 10-Year EV-to-EBIT Range
Min: 4.1   Max: 33
Current: 15.02

4.1
33
PEG 1.23
PMD's PEG is ranked higher than
85% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. PMD: 1.23 )
PMD' s 10-Year PEG Range
Min: 0.48   Max: 10.07
Current: 1.23

0.48
10.07
Shiller P/E 29.04
PMD's Shiller P/E is ranked higher than
75% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.47 vs. PMD: 29.04 )
PMD' s 10-Year Shiller P/E Range
Min: 5.39   Max: 45.98
Current: 29.04

5.39
45.98

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.60
PMD's Dividend Yield is ranked higher than
93% of the 54 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.28 vs. PMD: 3.60 )
PMD' s 10-Year Dividend Yield Range
Min: 1.96   Max: 18.28
Current: 3.6

1.96
18.28
Dividend Payout 0.96
PMD's Dividend Payout is ranked lower than
67% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.27 vs. PMD: 0.96 )
PMD' s 10-Year Dividend Payout Range
Min: 0.46   Max: 10
Current: 0.96

0.46
10
Dividend growth (3y) 7.70
PMD's Dividend growth (3y) is ranked higher than
78% of the 18 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.20 vs. PMD: 7.70 )
PMD' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 26
Current: 7.7

0
26
Yield on cost (5-Year) 4.17
PMD's Yield on cost (5-Year) is ranked higher than
89% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. PMD: 4.17 )
PMD' s 10-Year Yield on cost (5-Year) Range
Min: 2.27   Max: 21.19
Current: 4.17

2.27
21.19
Share Buyback Rate -0.60
PMD's Share Buyback Rate is ranked higher than
85% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.60 vs. PMD: -0.60 )
PMD' s 10-Year Share Buyback Rate Range
Min: 1.9   Max: -4.1
Current: -0.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 26.32
PMD's Price/Net Current Asset Value is ranked lower than
64% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.65 vs. PMD: 26.32 )
PMD' s 10-Year Price/Net Current Asset Value Range
Min: 4.75   Max: 124.07
Current: 26.32

4.75
124.07
Price/Tangible Book 7.30
PMD's Price/Tangible Book is ranked lower than
55% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. PMD: 7.30 )
PMD' s 10-Year Price/Tangible Book Range
Min: 3.18   Max: 12.81
Current: 7.3

3.18
12.81
Price/DCF (Projected) 2.11
PMD's Price/DCF (Projected) is ranked higher than
62% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. PMD: 2.11 )
PMD' s 10-Year Price/DCF (Projected) Range
Min: 0.68   Max: 4.93
Current: 2.11

0.68
4.93
Price/Median PS Value 1.19
PMD's Price/Median PS Value is ranked higher than
63% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. PMD: 1.19 )
PMD' s 10-Year Price/Median PS Value Range
Min: 0.53   Max: 4.48
Current: 1.19

0.53
4.48
Price/Peter Lynch Fair Value 1.26
PMD's Price/Peter Lynch Fair Value is ranked higher than
77% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. PMD: 1.26 )
PMD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.71   Max: 4.37
Current: 1.26

0.71
4.37
Price/Graham Number 2.75
PMD's Price/Graham Number is ranked lower than
51% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. PMD: 2.75 )
PMD' s 10-Year Price/Graham Number Range
Min: 1.27   Max: 14.51
Current: 2.75

1.27
14.51
Earnings Yield (Greenblatt) 6.70
PMD's Earnings Yield (Greenblatt) is ranked higher than
76% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. PMD: 6.70 )
PMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3   Max: 24.3
Current: 6.7

3
24.3
Forward Rate of Return (Yacktman) 20.83
PMD's Forward Rate of Return (Yacktman) is ranked higher than
92% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.75 vs. PMD: 20.83 )
PMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -11.4   Max: 40.7
Current: 20.83

-11.4
40.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Psychemedics Corporation is a Delaware corporation organized on September 24, 1986. The Company provides testing services for the detection of abused substances through the analysis of hair samples. The Company is a provider of hair testing for drugs of abuse, utilizing a patented hair analysis method involving radioimmunoassay technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company provides commercial testing and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, methamphetamine (including Ecstasy, which is difficult to detect in urine due to sporadic use patterns and rapid clearance from the body) and opiates (including heroin, hydrocodone, hydromorphone and oxycodone). The Company's customers include Fortune 500 companies, as well as small to mid-size corporations, schools and governmental entities located mainly in the United States. The Company currently serves hundreds of schools throughout the United States and in several foreign countries. The Company offers its school clients the same five-drug screen with mass spectrometry confirmation that is used with the Company's workplace testing service. The Company also offers a personal drug testing service, known as 'PDT-90', for parents concerned about drug use by their children. It allows parents to collect a small sample from their child in the privacy of the home, send it to the Company's laboratory and have it tested for drugs of abuse by the Company. The PDT-90 testing service uses the same patented method that is used with the Company's workplace testing service. The Company competes directly with numerous commercial laboratories that test for drugs mainly through urinalysis testing. Most of the laboratories are Laboratory Corporation of America and Quest Diagnostics. The Company is licensed as a clinical laboratory by the State of California as well as certain other states.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide